<DOC>
	<DOC>NCT00439426</DOC>
	<brief_summary>This single arm study will assess the efficacy and safety of Xeloda + oxaliplatin when given as first line treatment for patients with metastatic nasopharyngeal cancer. Patients will receive Xeloda (1000mg/m2 bid orally from day 1 to day 14, followed by a rest period of 7 days) plus oxaliplatin (130mg/m2 iv infusion on day 1 of each 21 day cycle) for 6-8 cycles. The anticipated time on study treatment is until disease progression, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.</brief_title>
	<detailed_description />
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>adult patients, 1875 years of age; history of nasopharyngeal cancer and distant metastases; no previous chemotherapy in past 6 months; recovery from previous radiotherapy; ability to swallow and retain oral medication. previous cytotoxic chemotherapy; radiotherapy within 4 weeks of treatment start; history of another malignancy within the last 5 years; clinically significant cardiac disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>